|
|
 |
| |
 |
|
|
|
Research remains a cornerstone of LifeCell’s long-term growth strategy and today, 10 major research initiatives are underway; several of which seek to leverage our core understanding of tissue and cellular engineering technology in order to develop new biologics that fulfill unmet clinical needs. Our many research initiatives are funded both by product sales - this past year, we invested 14% of product sales into research - and by grants obtained through external organizations - including the National Institutes of Health, which awarded LifeCell a $1.1 million grant in 2003.
Our strategy balances research dollars among short-, mid- and long-term projects, helping to ensure a future stream of innovative new products. Short-term projects are designed to extend the use of our tissue matrix into new markets, such as breast reconstruction applications. Mid-term initiatives apply our core technology to non-dermal tissues and long-term projects focus on understanding and exploiting the therapeutic potential of the extracellular matrix. While many of these initiatives are grounded in the experiences of customers, our internal Scientific Review Board is instrumental in helping us assess opportunities and in guiding our ongoing research and development efforts.
Our team of scientists are globally renowned for their expertise with the extracellular matrix and are currently involved in a wide range of research activities spanning multiple therapeutic areas, including reconstructive surgery, orthopedics and cardiovascular applications. The future for LifeCell holds tremendous promise, as we choose to invest only in those large market segments in which significant unmet clinical needs exist. |
|
|
|
|